Compostions and methods for diagnosis of axial pain with or without radiculopathy

Patent metadata

Field	Value
Publication number	US-10098970-B2
Application number	US-201715484877-A
Country	US
Kind code	B2
Filing date	Apr 11, 2017
Priority date	Jun 8, 2006
Publication date	Oct 16, 2018
Grant date	Oct 16, 2018

Abstract

The invention provides methods and composition developed to be used with imaging techniques and useful for diagnosis and monitoring the pain generator(s) of axial pain with or without radiculopathy and methods for screening therapeutic compounds potentially useful for treating axial pain with or without radiculopathy. Alternatively, degenerated discs can be monitored and treated before occurrence of a pathological pain condition. Pain markers and markers of degeneration include markers of neuronal, vascular, immune and matrix elements.

First claim

The invention claimed is:

1. A method of diagnosing a pain generator or a potential pain generator of axial pain conditions with or without associated arm or leg radicular pain in a patient comprising: administering a composition comprising a first compound, wherein the first compound comprises an isolated pain marker or an isolated marker of degeneration linked to a label combined with a therapeutic agent; and a second compound, wherein the second compound comprises an activator, wherein the activator is capable of activating receptors and increasing the signal derived from the pain marker or the marker of degeneration linked to the label, wherein the pain marker is selected from the group consisting of capsaicin or capsaicin derivatives.

2. The method of claim 1 , wherein the activator is capable of activating neuronal receptors.

3. The method of claim 1 , wherein the pain marker or the marker of degeneration is labeled with a radioisotope or fluorochrome.

4. The method of claim 3 , wherein the radioisotope is selected from the group consisting of 18F, 3H, 124I, 125I, 131I, 35S, 14C, 11C, and any combination thereof.

5. The method of claim 3 , wherein the fluorochrome is selected from the group consisting of fluorescein, dansyl, phycoerythryn, phycocyanin, allophycocyanin, O-phtaldehyde, fluorescamine, 152Eu+, and any combination thereof.

6. The method of claim 1 , wherein the activator is bradykinin.

7. The method of claim 1 , wherein the activator is acetylcholine.

8. The method of claim 1 , wherein the activator is adrenaline.

9. The method of claim 1 , wherein the activator is epinephrine.

10. The method of claim 1 , wherein the activator is camphor.

11. The method of claim 1 , wherein the activator is menthol.

12. The method of claim 1 , wherein the activator is piperine.

13. The method of claim 1 , wherein the activator is mustard oil.

14. The method of claim 1 , wherein the activator is curcumin.

15. The method of claim 1 , wherein the activator is eugenol.

16. The method of claim 1 , wherein the activator is histamine.

17. The method of claim 1 , where in the activator comprises at least one of bradykinin, acetylcholine, adrenaline, epinephrine, camphor, menthol, piperine, mustard oil, curcumin, eugenol, and histamine.

18. The method of claim 1 , wherein the capsaicin derivative is Z-Capsaicin, or N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide (Capsazepine).

Assignees

• Warsaw Orthopedic Inc
• Medtronic Inc

Inventors

• Mckay William F
• Gross Jeffrey M
• Trieu Hai
• Roy Josee
• Drapeau Susan J
• Schendel Michael J
• Walsh Andrew J Lowenthal

Classifications

• A61K49/0004 Primary

  Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title

• A61K49/00 Primary

  Preparations for testing in vivo · CPC title